Isomorphic Labs raises $2.1 billion in Series B funding
Led by Thrive Capital, with participation from Alphabet, GV, and new investors.
See the latest news and media coverage for Isomorphic Labs. We track all announcements, press releases, and industry mentions in real time, all in one place.
AI-driven drug discovery company
isomorphiclabs.comLast updated
In short: Isomorphic Labs secured $2.1 billion in Series B funding and prepared for its first human clinical trials of AI-designed drugs by late 2026.
Led by Thrive Capital, with participation from Alphabet, GV, and new investors.
The award recognizes their work with Novartis on AI-driven drug discovery. They aim to accelerate new medicines to patients.
The engine outperforms benchmarks, models induced fits and cryptic pockets, and explores new chemical space for drug design.
IsoDDE surpasses AlphaFold 3 in protein-ligand prediction, binding affinities, and pocket identification, advancing AI-driven drug discovery.
Isomorphic Labs, the Google DeepMind spin-off on a mission to “solve all disease” with artificial intelligence, has secured $2.1 billion in Series B funding ...
I profiled Hassabis and Isomorphic earlier this year, and caught up with him recently as the company hit a new milestone: This month, Isomorphic raised...
Abu Dhabi’s MGX, a tech-focused investment firm, has invested in Isomorphic Labs, a UK-based drug design and development company. The state-backed firm was among the...
That ambitious goal landed him $2.1 billion in Series B funding for Isomorphic Labs, a newish venture he founded and serves as the CEO of...
Track Isomorphic Labs and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to Isomorphic Labs and other trending companies.